These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9462271)

  • 1. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.
    Kennedy AD; King G; Kerr KM
    J Clin Pathol; 1997 Oct; 50(10):859-62. PubMed ID: 9462271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
    González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
    Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
    Osborn M; Pelling N; Walker MM; Fisher C; Nicholson AG
    Histopathology; 2002 Oct; 41(4):301-7. PubMed ID: 12383211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin.
    Attanoos RL; Goddard H; Thomas ND; Jasani B; Gibbs AR
    Histopathology; 1995 Oct; 27(4):361-6. PubMed ID: 8847067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
    Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
    J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
    Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
    Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology.
    Fetsch PA; Abati A; Hijazi YM
    Cancer; 1998 Apr; 84(2):101-8. PubMed ID: 9570213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
    Attanoos RL; Goddard H; Gibbs AR
    Histopathology; 1996 Sep; 29(3):209-15. PubMed ID: 8884348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
    Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
    Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
    Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
    Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
    Roberts F; Harper CM; Downie I; Burnett RA
    Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
    Ordóñez NG
    Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic value of thrombomodulin immunolocalization in serous effusions.
    Ascoli V; Scalzo CC; Taccogna S; Nardi F
    Arch Pathol Lab Med; 1995 Dec; 119(12):1136-40. PubMed ID: 7503662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
    Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
    Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma.
    Spagnolo DV; Whitaker D; Carrello S; Radosevich JA; Rosen ST; Gould VE
    Am J Clin Pathol; 1991 Mar; 95(3):322-9. PubMed ID: 1705090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
    Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
    Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.